Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies.
Location: Dominican Republic, Distrito Nacional, Santo Domingo
Employees: 1001-5000
Investors 1
| Date | Name | Website |
| 10.05.2022 | Water Stre... | waterstree... |
Mentions in press and media 13
| Date | Title | Description |
| 24.06.2025 | Double Bond Pharmaceutical Re-engages Global CRO Allucent to Accelerate Phase 1 Clinical Trial for Glioblastoma Candidate SI-053 | Double Bond Pharmaceutical Re-engages Global CRO Allucent to Accelerate Phase 1 Clinical Trial for Glioblastoma Candidate SI-053 Tue, Jun 24, 2025 08:00 CET Report this content Double Bond Pharmaceutical International AB (publ) ("DBP&q... |
| 15.04.2025 | Shifting Frontiers: Navigating the Evolution of Cell and Gene Therapies from Oncology to Autoimmune Studies, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, gain an understanding of the market shift of cell and gene therapies (CGTs) beyond cancer to address autoimmune diseases. Attendees will learn how innovative immunomodulatory techniques are enabling ne... |
| 30.01.2025 | Maximizing Therapeutic Success in Rare Diseases through Basket & Umbrella Trial Designs, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, learn about the trial design benefits and challenges presented by basket and umbrella trials. Attendees will gain insights into adaptive medical monitoring strategies crucial for supporting master prot... |
| 21.11.2024 | Inspection Readiness and the Updated ICH E6 R3: What to Anticipate, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, learn essential strategies for inspection readiness, with insights on the updated ICH E6 R3 guidelines, risk-proportionate approaches and how to build a robust compliance program. Attendees will gain i... |
| 17.09.2024 | Pharmacovigilance in a Global Market: Key Compliance Strategies, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, gain insights into the current and future challenges of globalization in pharmacovigilance (PV). Attendees will learn about the PV regulatory inspection landscape, including key differences and commona... |
| 14.08.2024 | Advancing Precision Oncology: Radionuclide Conjugate and Antibody-Drug Conjugate (ADC) Development Strategies, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, learn about the current landscape of antibody-drug conjugates and radionuclide conjugates. Attendees will gain insights into regulatory constructs, submission readiness, dose structuring and optimizati... |
| 22.05.2024 | The Changing Paradigm of Regulatory Submissions: Embracing Automation, Gen AI, and Innovation for Faster Approvals, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, learn about the current landscape as well as the future of regulatory submissions, including the emerging trends in regulatory writing such as generative artificial intelligence (AI), automation and le... |
| 15.05.2024 | Allucent Receives BARDA-Funded Project NextGen Award to Support a COVID-19 Vaccine Decentralized Clinical Trial | Allucent Will Conduct New Decentralized Phase IV Study Aimed at Counteracting Future Coronavirus Strains and Variants CARY, N.C., May 15, 2024 /PRNewswire/ -- Allucent, a global mid-sized clinical research organization (CRO), announced toda... |
| 14.11.2022 | Risk Assessment: Traditional and Novel Approaches to Assess and Manage Risks, Upcoming Webinar Hosted by Xtalks | Modeling approaches enable extrapolation of data from preclinical species to humans using established physiological differences. TORONTO (PRWEB) November 14, 2022 Risk assessment is a complex process intended to protect human health by iden... |
| 17.10.2022 | Benefits of Bayesian Dose Escalation Designs for Oncology Studies, Upcoming Webinar Hosted by Xtalks | These flexible methods may be more appropriate than those initially designed for chemotherapy drug development. TORONTO (PRWEB) October 17, 2022 As acceptance of flexible trial designs continues to advance, many sponsors are increasingly ex... |
Show more